The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Pentixapharm Holding AG's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Pentixapharm Holding AG's average Accounts Receivable for the
three
months ended in Mar. 2026 was €0.02 Mil.
Pentixapharm Holding AG (FRA:PTP) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Pentixapharm Holding AG Receivables Turnover Related Terms
Pentixapharm Holding AG Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Pentixapharm Holding AG's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pentixapharm Holding AG Receivables Turnover Chart
FRA:PTP vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Pentixapharm Holding AG's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pentixapharm Holding AG Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Pentixapharm Holding AG's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pentixapharm Holding AG (FRA:PTP) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pentixapharm Holding AG and its competitors. According to the industry distribution chart, Pentixapharm Holding AG ranks #628 out of 846 companies in the Biotechnology industry, placing it in the top 74.2%.
Is Pentixapharm Holding AG's Receivables Turnover too high?
Pentixapharm Holding AG's current Receivables Turnover is 0.00. Based on the distribution chart, Pentixapharm Holding AG ranks #628 out of 846 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pentixapharm Holding AG has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pentixapharm Holding AG ranks #628 out of 846 companies for Receivables Turnover. This places Pentixapharm Holding AG in the lower half of its industry. The industry median Receivables Turnover is 5.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Pentixapharm Holding AG and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pentixapharm Holding AG's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (FRA:PTP) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Pentixapharm Holding AG's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Pentixapharm Holding AG (FRA:PTP), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score
Get the complete analysis for FRA:PTP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PTP has been successfully added to your 
